Vulvar neoplasm

disease
On this page

Also known as mammalian vulva neoplasmmammalian vulva neoplasm (disease)mammalian vulva tumormammalian vulva tumourneoplasm of mammalian vulvaneoplasm of the vulvaneoplasm of vulvatumor of mammalian vulvatumor of the vulvatumor of vulvatumour of mammalian vulvatumour of the vulvatumour of vulvavulva neoplasmvulva tumorvulva tumourvulval neoplasmvulvar tumorvulvar tumour

Summary

Vulvar neoplasm (MONDO:0021049) is a cancer (an umbrella term covering 9 Mondo subtypes) and 18 clinical trials. Top therapeutic interventions include hydroxyzine, loperamide, and prochlorperazine. A subtype of vulvar disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Umbrella term: 9 Mondo subtypes
  • Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namevulvar neoplasm
Mondo IDMONDO:0021049
NCITC3443
SNOMED CT126922007
UMLSC0042995
MedGen22689
Anatomy (UBERON)UBERON:0000997
Is cancer (heuristic)yes

Also known as: mammalian vulva neoplasm · mammalian vulva neoplasm (disease) · mammalian vulva tumor · mammalian vulva tumour · neoplasm of mammalian vulva · neoplasm of the vulva · neoplasm of vulva · tumor of mammalian vulva · tumor of the vulva · tumor of vulva · tumour of mammalian vulva · tumour of the vulva · tumour of vulva · vulva neoplasm · vulva tumor · vulva tumour · vulval neoplasm · vulvar neoplasm · vulvar tumor · vulvar tumour

Disease family

This is a subtype of vulvar disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorderfemale reproductive system disordervulvar diseasevulvar neoplasm

Related subtypes (3): ulceration of vulva, vulvar dystrophy, vulvitis

Subtypes (9): vulvar benign neoplasm, vulva cancer, vulvar squamous neoplasm, vulvar glandular neoplasm, paraurethral gland neoplasm, vulvar granular cell tumor, germ cell tumor of the vulva, Bartholin gland neoplasm, clitoris neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified11
PHASE32
PHASE1/PHASE22
PHASE22
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00224744PHASE3COMPLETEDProspective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage
NCT03546842PHASE3COMPLETEDSafety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
NCT05592626PHASE1/PHASE2RECRUITINGA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT06638931PHASE2RECRUITINGAgnostic Therapy in Rare Solid Tumors
NCT02858310PHASE1/PHASE2COMPLETEDE7 TCR T Cells for Human Papillomavirus-Associated Cancers
NCT05761132PHASE2UNKNOWNNeo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
NCT05578820PHASE1COMPLETEDSafety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
NCT05934851Not specifiedACTIVE_NOT_RECRUITINGA Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia
NCT06132321Not specifiedRECRUITINGQuality of Life in Patients Undergone Vulvar Reconstruction After Vulvar Cancer Resection (3233)
NCT06495554Not specifiedRECRUITINGDanish Vulva Cancer Recurrence Study
NCT00112307Not specifiedCOMPLETEDMagnetic Resonance Imaging Guided Gynecologic Brachytherapy
NCT00288821Not specifiedCOMPLETEDDiagnostic Imaging of Lymph Nodes in Gynaecologic Oncology
NCT00391664Not specifiedUNKNOWNQuestionnaire Study for Gynecological Cancer Survivors
NCT02067052Not specifiedUNKNOWNNew Strategy for the Treatment of Vulvar Cancer
NCT02786524Not specifiedCOMPLETEDEffect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
NCT03000192Not specifiedUNKNOWNHORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
NCT04351139Not specifiedCOMPLETEDImpact of the COVID-19 Pandemic in Gynecological Oncology
NCT04541784Not specifiedCOMPLETEDEffectiveness of an App Intervention to Reduce Postsurgical Symptom Distress in Patients With Vulvar Neoplasia

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
HYDROXYZINE43
LOPERAMIDE43
PROCHLORPERAZINE43
ATROPINE SULFATE41
CODEINE SULFATE41
DIPHENHYDRAMINE HYDROCHLORIDE41
DIPHENOXYLATE HYDROCHLORIDE41
DROPERIDOL41
FLUDARABINE PHOSPHATE41
GANCICLOVIR41
GRANISETRON41
INDOMETHACIN41
MEPERIDINE41
CHEMBL28467101
CHEMBL39953801